PMID- 19126942 OWN - NLM STAT- MEDLINE DCOM- 20090331 LR - 20161124 IS - 0019-4832 (Print) IS - 0019-4832 (Linking) VI - 59 IP - 4 DP - 2007 Jul-Aug TI - Heparin induced thrombocytopenia management with bivalirudin. PG - 354-5 AB - We report a case of Heparin Induced Thrombocytopenia (HIT) following percutaneous coronary intervention. The case is unique in that thrombocytopenia occurred very early after heparin administration and responded well to a regime of bivalirudin-a direct thrombin inhibitor readily available in India. Heparin, Thrombocytopenia, Bivalirudin Acute HIT, occurring within few hours of heparin therapy have been reported in patients previously exposed to unfractionated heparin (UFH) or low molecular weight heparin (LMWH) 1. Prompt recognition of the condition and timely intervention with direct thrombin inhibitors, can result in salvaging patients from this potentially fatal complication. FAU - Meera, R AU - Meera R AD - Department of Cardiology, Kerala Institute of Medical Sciences, Trivandrum, Kerala. meeradocpillai@yahoo.com FAU - Rachel, D AU - Rachel D FAU - Ramakrishnapillai, V AU - Ramakrishnapillai V FAU - Vijayaraghavan, G AU - Vijayaraghavan G LA - eng PT - Case Reports PT - Journal Article PL - India TA - Indian Heart J JT - Indian heart journal JID - 0374675 RN - 0 (Anticoagulants) RN - 0 (Hirudins) RN - 0 (Peptide Fragments) RN - 0 (Recombinant Proteins) RN - 9005-49-6 (Heparin) RN - TN9BEX005G (bivalirudin) SB - IM CIN - Indian Heart J. 2007 Jul-Aug;59(4):297-8. PMID: 19126932 MH - Anticoagulants/*adverse effects/*therapeutic use MH - Heparin/*adverse effects MH - Hirudins MH - Humans MH - Male MH - Middle Aged MH - Myocardial Infarction/*therapy MH - Peptide Fragments/*therapeutic use MH - Recombinant Proteins/therapeutic use MH - Thrombocytopenia/*chemically induced EDAT- 2007/07/01 00:00 MHDA- 2009/04/01 09:00 CRDT- 2009/01/08 09:00 PHST- 2009/01/08 09:00 [entrez] PHST- 2007/07/01 00:00 [pubmed] PHST- 2009/04/01 09:00 [medline] PST - ppublish SO - Indian Heart J. 2007 Jul-Aug;59(4):354-5.